Top

Published in:

01-12-2015 | Research Article

Antitumor effects evaluation of a novel porphyrin derivative in photodynamic therapy

Authors: Jian-Wei Li, Zhong-Ming Wu, Davor Magetic, Li-Jun Zhang, Zhi-Long Chen

Published in: Tumor Biology | Issue 12/2015

Abstract

In this paper, the antitumor activity of a novel porphyrin-based photosensitizer 5,10,15,20-tetrakis[(5-diethylamino)pentyl] porphyrin (TDPP) was reported in vitro and in vivo. The photophysical and cellular properties of TDPP were investigated. The singlet oxygen generation quantum yield of TDPP was detected; it showed a high singlet oxygen quantum yield of 0.52. The intracellular distribution of photosensitizer was detected with laser scanning confocal microscopy. The efficiency of TDPP-photodynamic therapy (PDT) in vitro was analyzed by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay and in situ trypan blue exclusion test. Treated with a 630-nm laser, TDPP can kill cultured human esophageal cancer cell line (Eca-109) cells and reduce the growth of Eca-109 xenograft tumors significantly in BABL/c nude mice. And histopathological study was also used to confirm the antitumor effect. It has the perspective to be developed as a new antitumor drug in photodynamic therapy and deserves further investigation.

Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, et al. Photodynamic therapy. J Natl Cancer Inst. 1998;90(12):889–905.CrossRefPubMedPubMedCentral

MacCormack MA. Photodynamic therapy. Adv Dermatol. 2006;22:219–58.CrossRefPubMed

Celli JP, Spring BQ, Rizvi I, Evans CL, Samkoe KS, Verma S, et al. Imaging and photodynamic therapy: mechanisms, monitoring, and optimization. Chem Rev. 2010;110(5):2795–838. doi:10.1021/cr900300p.CrossRefPubMedPubMedCentral

Dougherty TJ. Photodynamic therapy: part II. Semin Surg Oncol. 1995;11(5):333–4.CrossRefPubMed

Castano AP, Mroz P, Hamblin MR. Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer. 2006;6(7):535–45. doi:10.1038/nrc1894.CrossRefPubMedPubMedCentral

Triesscheijn M, Baas P, Schellens JH, Stewart FA. Photodynamic therapy in oncology. Oncologist. 2006;11(9):1034–44. doi:10.1634/theoncologist.11-9-1034.CrossRefPubMed

Allison RR, Moghissi K. Photodynamic therapy (PDT): PDT mechanisms. Clinical Endoscopy. 2013;46(1):24–9. doi:10.5946/ce.2013.46.1.24.CrossRefPubMedPubMedCentral

Ethirajan M, Chen Y, Joshi P, Pandey RK. The role of porphyrin chemistry in tumor imaging and photodynamic therapy. Chem Soc Rev. 2011;40(1):340–62. doi:10.1039/b915149b.CrossRefPubMed

Zhang LJ, Bian J, Bao LL, Chen HF, Yan YJ, Wang L, et al. Photosensitizing effectiveness of a novel chlorin-based photosensitizer for photodynamic therapy in vitro and in vivo. J Cancer Res Clin Oncol. 2014;140(9):1527–36. doi:10.1007/s00432-014-1717-0.CrossRefPubMed

10.

Yan YJ, Zheng MZ, Chen ZL, Yu XH, Yang XX, Ding ZL, et al. Studies on preparation and photodynamic mechanism of chlorin p 6–13,15-N-(cyclohexyl)cycloimide (Chlorin-H) and its antitumor effect for photodynamic therapy in vitro and in vivo. Bioorg Med Chem. 2010;18(17):6282–91. doi:10.1016/j.bmc.2010.07.027.CrossRefPubMed

11.

O'Connor AE, Gallagher WM, Byrne AT. Porphyrin and nonporphyrin photosensitizers in oncology: preclinical and clinical advances in photodynamic therapy. Photochem Photobiol. 2009;85(5):1053–74. doi:10.1111/j.1751-1097.2009.00585.x.CrossRefPubMed

12.

Kempa M, Kozub P, Kimball J, Rojkiewicz M, Kus P, Gryczynski Z, et al. Physicochemical properties of potential porphyrin photosensitizers for photodynamic therapy. Spectrochim Acta A Mol Biomol Spectrosc. 2015;146:249–54. doi:10.1016/j.saa.2015.03.076.CrossRefPubMed

13.

Zenkevich EI. Structural dynamics and relaxation processes with participation of excited singlet and triplet states in sterically hindered porphyrins and their chemical dimers. Macroheterocycles. 2014;7(2):103–21. doi:10.6060/Mhc140597z.CrossRef

14.

Serra AC, Pineiro M, Rocha Gonsalves AM, Abrantes M, Laranjo M, Santos AC, et al. Halogen atom effect on photophysical and photodynamic characteristics of derivatives of 5,10,15,20-tetrakis(3-hydroxyphenyl)porphyrin. J Photochem Photobiol B Biol. 2008;92(1):59–65. doi:10.1016/j.jphotobiol.2008.04.006.CrossRef

15.

Stylli SS, Howes M, MacGregor L, Rajendra P, Kaye AH. Photodynamic therapy of brain tumours: evaluation of porphyrin uptake versus clinical outcome. J Clin Neurosci. 2004;11(6):584–96. doi:10.1016/j.jocn.2004.02.001.CrossRefPubMed

16.

Milanesio ME, Moran FS, Yslas EI, Alvarez MG, Rivarola V, Durantini EN. Synthesis and biological evaluation of methoxyphenyl porphyrin derivatives as potential photodynamic agents. Bioorg Med Chem. 2001;9(8):1943–9.CrossRefPubMed

17.

Juarranz A, Jaen P, Sanz-Rodriguez F, Cuevas J, Gonzalez S. Photodynamic therapy of cancer. Basic principles and applications. Clin Translat Oncology Off Public Fed Spanish Oncol Soc National Cancer Inst of Mexico. 2008;10(3):148–54.

18.

Redmond RW, Gamlin JN. A compilation of singlet oxygen yields from biologically relevant molecules. Photochem Photobiol. 1999;70(4):391–475.CrossRefPubMed

19.

Hampton JA, Selman SH. Mechanisms of cell killing in photodynamic therapy using a novel in vivo drug/in vitro light culture system. Photochem Photobiol. 1992;56(2):235–43.CrossRefPubMed

20.

Stockert JC, Canete M, Juarranz A, Villanueva A, Horobin RW, Borrell JI, et al. Porphycenes: facts and prospects in photodynamic therapy of cancer. Curr Med Chem. 2007;14(9):997–1026.CrossRefPubMed

21.

van Hillegersberg R, Kort WJ, Wilson JH. Current status of photodynamic therapy in oncology. Drugs. 1994;48(4):510–27.CrossRefPubMed

22.

Stylli SS, Kaye AH. Photodynamic therapy of cerebral glioma—a review part I—a biological basis. J Clin Neurosci Off J Neurosurg Soc Australasia. 2006;13(6):615–25. doi:10.1016/j.jocn.2005.11.014.

23.

Lim YC, Yoo JO, Park D, Kang G, Hwang BM, Kim YM, et al. Antitumor effect of photodynamic therapy with chlorin-based photosensitizer DH-II-24 in colorectal carcinoma. Cancer Sci. 2009;100(12):2431–6. doi:10.1111/j.1349-7006.2009.01326.x.CrossRefPubMed

Title: Antitumor effects evaluation of a novel porphyrin derivative in photodynamic therapy
Authors: Jian-Wei Li
Zhong-Ming Wu
Davor Magetic
Li-Jun Zhang
Zhi-Long Chen
Publication date: 01-12-2015
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 12/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-3745-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2015

Long noncoding RNA HOTAIR, a hypoxia-inducible factor-1α activated driver of malignancy, enhances hypoxic cancer cell proliferation, migration, and invasion in non-small cell lung cancer

Plakophilin 1-deficient cells upregulate SPOCK1: implications for prostate cancer progression

Association between cell cycle gene transcription and tumor size in oral squamous cell carcinoma

Quercetin 3-O-glucoside suppresses epidermal growth factor–induced migration by inhibiting EGFR signaling in pancreatic cancer cells

Correlation between serum levels of vascular endothelial growth factor-C and sentinel lymph node status in early breast cancer

Transforming growth factor β type II receptor as a marker in diffuse large B cell lymphoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer